SLGL insider trading
NasdaqCM HealthcareSol-Gel Technologies Ltd.: insider trade history from SEC Form 4 filings.
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Company website: www.sol-gel.com
SLGL insider activity at a glance
FilingIQ tracks 49 insider transactions for SLGL in filings since Nov 21, 2025. The most recent transaction is dated Sep 11, 2026.
Across the full history, 49 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SLGL insider trades is 48.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SLGL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for SLGL?
- FilingIQ tracks 49 Form 4 insider transactions for SLGL (Sol-Gel Technologies Ltd.), covering filings from Nov 21, 2025 onwards. 18 of those are dated within the last 90 days.
- Are SLGL insiders net buyers or net sellers?
- Across the full Form 4 history for SLGL, 49 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SLGL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is SLGL in?
- Sol-Gel Technologies Ltd. (SLGL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $222.89M.
Methodology & sources
Every SLGL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.